SEC Form 4 · accession 0001796536-26-000007
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Corazon (Corsee) D. Sanders
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 15, 2026 · 6:50 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2026 | S | 2,000 | $25.05 | D | 21,095 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.